Chebib FT, Zhou X, Garbinsky D, Davenport E, Nunna S, Oberdhan D, Fernandes A. Tolvaptan and kidney function decline in older individuals with autosomal dominant polycystic kidney disease: a pooled analysis of randomized clinical trials and observational studies. Kidney Med. 2023 Jun;5(6):100639. doi: 10.1016/j.xkme.2023.100639
Fliser D, Lorenzo MM, Houghton K, Ainsworth C, Blogg M, Gonzalez de Antona Sanchez E, Portles J. Real-life anemia management among patients with non-dialysis-dependent chronic kidney disease in three European countries. Int J Nephrol Renovasc Dis. 2023 Apr 13;16:115-29. doi: 10.2147/IJNRD.S401598
Herring WL, Gould IG, Wittrup-Jensen V, Ertle J, Kuti E, Wolowacz S. Evaluation of emerging NASH therapies: the impact of treatment efficacy profiles on long-term health outcomes. J Comp Eff Res. 2022 Dec 1;11(18):1349-63. doi: 10.2217/cer-2021-0194
Joshi K, Muser E, Xu Y, Schwab P, Datar M, Suehs B. Adherence and economic impact of paliperidone palmitate versus oral atypical antipsychotics in a Medicare population. J Comp Eff Res. 2018 Aug;7(8):723-35. doi: 10.2217/cer-2018-0003
Meyers J, Gajria K, Candrilli SD, Fridman M, Sikirica V. The impact of adjunctive guanfacine extended release on stimulant adherence in children/adolescents with attention-deficit/hyperactivity disorder. J Comp Eff Res. 2017 Mar;6(2):109-25. doi: 10.2217/cer-2016-0039
McIntyre LF, Beach WR, Higgins LD, Mordin MM, Mauskopf J, Sweeney CT, Copley-Merriman C. Evidence-based medicine, appropriate-use criteria, and sports medicine: how best to develop meaningful treatment guidelines. Arthroscopy. 2013 Mar 18;29(7):1224-9.
Braun L, Sood V, Hogue S, Lieberman B, Copley-Merriman C. High burden and unmet patient needs in chronic kidney disease. Int J Nephrol Renovasc Dis. 2012 Dec 1;5:151-63.